Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $110.6 million.

  • Viridian Therapeutics, Inc.\DE's Operating Expenses rose 3233.01% to $110.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $398.9 million, marking a year-over-year increase of 4078.54%. This contributed to the annual value of $299.3 million for FY2024, which is 1749.58% up from last year.
  • Viridian Therapeutics, Inc.\DE's Operating Expenses amounted to $110.6 million in Q3 2025, which was up 3233.01% from $106.8 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Operating Expenses peaked at $110.6 million during Q3 2025, and registered a low of $14.3 million during Q3 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Operating Expenses value was $56.0 million (recorded in 2024), while the average stood at $57.1 million.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Operating Expenses in the last 5 years was 19177.62% (2021), contrasted with its biggest fall of 6768.41% (2021).
  • Viridian Therapeutics, Inc.\DE's Operating Expenses (Quarter) stood at $29.3 million in 2021, then skyrocketed by 67.85% to $49.2 million in 2022, then skyrocketed by 45.51% to $71.6 million in 2023, then grew by 22.35% to $87.5 million in 2024, then grew by 26.32% to $110.6 million in 2025.
  • Its Operating Expenses was $110.6 million in Q3 2025, compared to $106.8 million in Q2 2025 and $93.9 million in Q1 2025.